Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

264.34 -0.78 (-0.29%)

Official Closing Price Updated: 4:10 PM EDT, Sep 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? ↗

Today 17:22 EDT

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026? ↗

September 24, 2026

Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026? ↗

September 24, 2026

AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.

Via The Motley Fool

Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade ↗

September 24, 2026

It would be hard for investors to replicate the company's return over the past decade.

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September? ↗

September 22, 2026

These companies are committed to rewarding shareholders.

Via The Motley Fool

Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)

September 21, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its pe...

Via StockStory

Topics Artificial Intelligence

AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now? ↗

September 19, 2026

AbbVie's market-beating days don't seem to be over yet.

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 18, 2026

AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal uncertainty.

Via The Motley Fool

Topics Intellectual Property

Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded? ↗

September 16, 2026

The company is still looking to bounce back after the beating it took in recent years.

Via The Motley Fool

Topics Economy

Is AbbVie the Best Dividend King to Buy in September? ↗

September 16, 2026

It is certainly a good Dividend King to buy in September.

Via The Motley Fool

Topics Intellectual Property

3 Dividend Stocks That Are No-Brainer Buys Right Now, Starting With This Healthcare Giant ↗

September 15, 2026

These three stocks meet multiple criteria for long-term dividend investing success.

Via The Motley Fool

Topics Intellectual Property

AbbVie Maps Post-HUMIRA Growth With Apogee Deal, Immunology Pipeline ↗

September 15, 2026

AbbVie (NYSE:ABBV) executives outlined a pipeline and business-development strategy centered on immunology, neuroscience, oncology and obesity, while highlighting plans to expand beyond the company’s...

Via MarketBeat

Topics ETFs

Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside ↗

September 14, 2026

Citadel, Ken Griffin's hedge fund, materially increased its stake in AbbVie; here's why you may want to follow that lead.

Via The Motley Fool

Topics Economy Intellectual Property

AbbVie vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 14, 2026

AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.

Via The Motley Fool

Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock? ↗

September 12, 2026

AbbVie's dividend is a very appealing factor.

Via The Motley Fool

Topics Artificial Intelligence

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 10, 2026

AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.

Via The Motley Fool

Topics Intellectual Property

Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years ↗

September 09, 2026

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.17% on an annualized basis producing an average annual return of 14.76%. Currently, AbbVie has a market capitalization of...

Via Benzinga

AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference ↗

September 09, 2026

AbbVie (NYSE:ABBV) executives outlined growth plans across immunology, oncology and neuroscience at a Wells Fargo conference, emphasizing continued momentum for its SKYRIZI and RINVOQ franchises, a...

Via MarketBeat

2 Dividend Stocks Built to Hold Up When Markets Don't ↗

September 09, 2026

These two are on the Dividend Kings list.

Via The Motley Fool

Topics Artificial Intelligence Economy

Billionaire Israel Englander Is Doubling Down on These 2 Outstanding Dividend Stocks. Should You? ↗

September 09, 2026

Dividend seekers can hardly go wrong with these companies.

Via The Motley Fool

Topics Intellectual Property

If I Were in My 20s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever ↗

September 08, 2026

Low-cost index funds can be a ticket to prosperity for everyday investors.

Via The Motley Fool

Topics ETFs Economy

Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now ↗

September 08, 2026

Pfizer's 6% dividend yield is enticing, but AbbVie's dividend growth is superior.

Via The Motley Fool

Topics Intellectual Property

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It ↗

September 06, 2026

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

Via MarketBeat

Topics Artificial Intelligence Bonds

3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King) ↗

September 05, 2026

Owning these dividend stocks could be a simple way to make money over the long term.

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 04, 2026

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

Via The Motley Fool

Topics Intellectual Property

True Beauty Aesthetics Marks One-Year Milestone With Open House

September 02, 2026

MOUNT PLEASANT, SC - September 02, 2026 - Malissa LaRoche, PA-C, owner of True Beauty Aesthetics, is celebrating one year at the practice's current Mount Pleasant location this month, with...

Via Press Advantage

AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 29, 2026

Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.

Via The Motley Fool

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 29, 2026

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

Via The Motley Fool

If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today ↗

August 26, 2026

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.74% on an annualized basis producing an average annual return of 15.14%. Currently, AbbVie has a market capitalization of...

Via Benzinga

Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2. Wall Street Thinks It's Still a Buy. ↗

August 26, 2026

His AbbVie purchase was a big move into a high-yielding dividend stock.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.